

## INFORME DE BÚSQUEDA DE PATENTES

**N° de solicitud:** 16117710. Prioridad: 05/Noviembre/2013

**CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados\*. Para el caso de secuencias, anexar alineamientos)**

|                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>PALABRAS CLAVE UTILIZADAS</b> | <ol style="list-style-type: none"> <li>1. "Pyrimido[1,2-b]indazoles" "bleeding"</li> <li>2. "Fused pyrimidines" "bleeding"</li> <li>3. "Plasminogen inhibitors" "bleeding"</li> <li>4. "Fibrinolysis" "Bleeding disorders"</li> <li>4. "Fibrinolysis" "Stroke"</li> <li>5. "Fibrinolysis" "Menorragia"</li> <li>6. "Piperidinylpyrazolopyrimidinones" "Plasminogen inhibitors"</li> <li>7. "Plasminogen inhibitors" "(aza)pyridopyrazolopyrimidinones"</li> <li>8. "Plasminogen inhibitors" "Indazolopyrimidinones"</li> <li>9. "Fibrinolysis inhibitors" "Piperidinylpyrazolopyrimidinones"</li> <li>10. "Fibrinolysis inhibitors" "(aza)pyridopyrazolopyrimidinones"</li> <li>11. "Fibrinolysis inhibitors" "Indazolopyrimidinones"</li> <li>12. "Fibrosis inhibitory" "Menstrual Blood Loss"</li> <li>13. "Fibrosis inhibitory" "Severe bleeding"</li> <li>14. "Antifibrinolytic therapy" "Piperidinylpyrazolopyrimidinones"</li> <li>15. "Antifibrinolytic therapy" "(aza)pyridopyrazolopyrimidinones"</li> <li>16. "Antifibrinolytic therapy" "Indazolopyrimidinones"</li> <li>17. "Uterine bleeding" "Piperidinylpyrazolopyrimidinones"</li> <li>18. "Uterine bleeding" "(aza)pyridopyrazolopyrimidinones"</li> <li>19. "Uterine bleeding" "Indazolopyrimidinones"</li> <li>20. "Menorrhagia" "Fibrinolysis Inhibitor"</li> <li>21. "Bleeding disorders" "Fibrinolysis Inhibitor"</li> <li>22. "Fibrin formation" "(aza)pyridopyrazolopyrimidinones"</li> <li>23. "Fibrinolysis" "(aza)pyridopyrazolopyrimidinones"</li> <li>24. "Thrombin-activatable fibrinolysis inhibitor (TAFI)" "(aza)pyridopyrazolopyrimidinones"</li> <li>25. "Plasmin" "(aza)pyridopyrazolopyrimidinones"</li> <li>26. "fibrinolytic system" "(aza)pyridopyrazolopyrimidinones"</li> <li>27. "Plasminogen" "fibrinolysis attenuators"</li> <li>28. "Thrombin-activatable fibrinolysis inhibitor" "(aza)pyridopyrazolopyrimidinones"</li> <li>29. "Piperidinylpyrazolopyrimidinones" "Antifibrinolytic compounds"</li> <li>30. "BAYER PHARMA AKTIENGESELLSCHAFT" "Antifibrinolytic compounds"</li> <li>31. "BAYER PHARMA AKTIENGESELLSCHAFT" "(aza)pyridopyrazolo pyrimidinones"</li> <li>32. "Bleeding disorders" "BAYER PHARMA AKTIENGESELLSCHAFT"</li> <li>33. "Pyridopyrazolopyrimidinones" "Indazolopyrimidinones"</li> </ol> |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                    |                                                               |
|----------------------------------------------------|---------------------------------------------------------------|
| <b>CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA</b> | <b>CIP:</b> C07D 487/04, C07D 487/12, A61K 31/519, A61P 7/04. |
|                                                    | <b>CPC (Opcional):</b>                                        |

### DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)

| Informes/Base de datos | N° de solicitud/<br>Autor** | Fecha de<br>Publicación/Presentación<br>(DD/MM/AAAA) | Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias) | Categorías especiales de los documentos citados*** |
|------------------------|-----------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------|
| WO                     | WO2012080237                | 21/Junio/2012                                        |                                                                                                | A                                                  |
|                        | WO2012047156                | 12/Abril/2012                                        |                                                                                                | A                                                  |
|                        | WO2007088041                | 09/Agosto/2007                                       |                                                                                                | A                                                  |
|                        | WO2012082947                | 21/Junio/2012                                        |                                                                                                | A                                                  |
| Google                 | WO2008070016                | 12/Junio/2008                                        |                                                                                                | A                                                  |
|                        | WO2010091808                | 19/Agosto/2010                                       |                                                                                                | A                                                  |
|                        | US20110178107               | 21/Julio/2011                                        |                                                                                                | A                                                  |
|                        | WO2014012964                | 23/Junio/2014                                        |                                                                                                | A                                                  |

|       |                     |                    |  |   |
|-------|---------------------|--------------------|--|---|
| USPTO | <b>WO2012080237</b> | 21/Junio/2012      |  | A |
|       | <b>WO2012047156</b> | 12/Abril/2012      |  | A |
|       | <b>WO2007088041</b> | 09/Agosto/2007     |  | A |
| SIPI  | <b>16006928</b>     | 13/Enero/2016      |  | A |
|       | <b>15129807</b>     | 05/Junio/2015      |  | A |
|       | 14066898            | 28/Marzo/2014      |  | A |
|       | 14235151            | 23/Octubre/2014    |  | A |
|       | 04071464            | 26/Julio/2004      |  | A |
|       | 08010488            | 04/Febrero/2008    |  | A |
|       | 09119107            | 23/Octubre/2009    |  | A |
|       | 06095141            | 21/Septiembre/2006 |  | A |
|       | 11103122            | 12/Agosto/2011     |  | A |
| CN    | <b>CN101379056</b>  | 04/Marzo/2009      |  | A |
|       | <b>WO2012047156</b> | 12/Abril/2012      |  | A |
|       | <b>WO2012082947</b> | 21/Junio/2012      |  | A |
|       | <b>CN103370321</b>  | 23/Octubre/2013    |  | A |

“A” documento que define el estado general de la técnica no considerado como particularmente relevante.  
“E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior.  
“P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.  
“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado.  
“Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.

\*\*\*\* Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.

|                                                                                                           |            |                                                                                                                                                                   |          |        |            |                   |
|-----------------------------------------------------------------------------------------------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--------|------------|-------------------|
| <b>Literatura no patente</b><br>**Se incluye entre otros, toda la referencia de la literatura no patente. | -          | Menstrual                                                                                                                                                         | Blood    | Loss-A | Population | Study;            |
|                                                                                                           |            | <a href="https://obgyn.onlinelibrary.wiley.com/doi/full/10.3109/00016346609158455">https://obgyn.onlinelibrary.wiley.com/doi/full/10.3109/00016346609158455</a>   |          |        |            |                   |
|                                                                                                           |            | Antifibrinolytic                                                                                                                                                  | therapy: | new    | data       | and new concepts; |
|                                                                                                           |            | <a href="https://www.ncbi.nlm.nih.gov/pubmed/20554318">https://www.ncbi.nlm.nih.gov/pubmed/20554318</a>                                                           |          |        |            |                   |
|                                                                                                           | -Molecular | mechanisms                                                                                                                                                        |          |        |            | of fibrinolysis;  |
|                                                                                                           |            | <a href="https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2005.05444.x">https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2005.05444.x</a> |          |        |            |                   |

|                                       |               |
|---------------------------------------|---------------|
| <b>Fecha del reporte de búsqueda:</b> | 29/Marzo/2018 |
|---------------------------------------|---------------|

Username: sic8@patbase.com  
Subaccount: none

Menu - Search - History - Session - Folder - Order - Help - Logout

| #  | Search query                    | Results | Options                                   |
|----|---------------------------------|---------|-------------------------------------------|
| 10 | 9 and 3                         | 1       | View   Browse   Hits   Optimise   more... |
| 9  | Menstrual Blood Loss            | 21      | View   Browse   Hits   Optimise   more... |
| 8  | Antifibrinolytic therapy        | 5       | View   Browse   Hits   Optimise   more... |
| 7  | 1 and 6                         | 5       | View   Browse   Hits   Optimise   more... |
| 6  | BAYER PHARMA AKTIENGESELLSCHAFT | 69      | View   Browse   Hits   Optimise   more... |
| 5  | Indazolopyrimidinones           | 2       | View   Browse   Hits   Optimise   more... |
| 4  | Pyridopyrazolopyrimidinones     | 1       | View   Browse   Hits   Optimise   more... |
| 3  | 1 and 2                         | 7       | View   Browse   Hits   Optimise   more... |
| 2  | Fibrinolysis                    | 893     | View   Browse   Hits   Optimise   more... |
| 1  | STAC=(Bleeding disorders)       | 215     | View   Browse   Hits   Optimise   more... |

**Command Reference**  
Bibliographic data  
Textual data  
Update commands  
Operators  
Navigation / shortcuts  
  
**Search tools**  
Patent number formats  
PatBase Thesaurus  
Classification finder  
  
Register for a Webinar  
European Training Courses  
Video tutorials

Command line:  Search

PatBase has been developed in partnership by &

History - Internal

| Database ⓘ | SS | Status | Results | Query                       |
|------------|----|--------|---------|-----------------------------|
| EPODOC     | 1  |        | 36498   | BLEEDING                    |
|            | 2  |        | 750     | FIBRINOLYSIS                |
|            | 3  |        | 40      | 1 AND 2                     |
|            | 4  |        | 7084    | AZA                         |
|            | 5  |        | 6       | 4 AND 3                     |
|            | 6  |        | 9297    | BAYER                       |
|            | 7  |        | 5       | 1 AND 6                     |
|            | 8  |        | 417     | AKTIENGESELLSCHAFT          |
|            | 9  |        | 0       | 1 AND 8                     |
|            | 10 |        | 0       | 8 AND 2                     |
|            | 11 |        | 15      | PYRIDOPYRAZOLOPYRIMIDINONES |
|            | 12 |        | 0       | BAYER PHARMA                |
|            | 13 |        | 16      | INDAZOLOPYRIMIDINONES       |
|            | 14 |        | 10      | 13 AND 1                    |

☒ Keep dialog open

☐ Current Database

☒ All Databases

☐ Show metadata

☐ Expand rows (Cluste...

Save as preparation

Rank and View

Send to Viewer

Save as XFile

☐ Add to Current WL